HealthCare Global Enterprises Limited
Momentum (73/100) does the heavy lifting; quality (14/100) is the drag.
ExpensiveHealthCare Global Enterprises Limited earns a Sell from StocksWizard, with a blended score of 31/100. At ₹671.2 it trades above our blended DCF and relative-multiples fair value of ₹605.94, about 10% downside to that estimate — we read it as fairly valued. The price is about 14% below its 52-week high of ₹776.3 and 29% above the low of ₹521.75. Financial health scores 43/100, in the grey band on the Altman Z-score, with a Piotroski F-score of 6/9. The average analyst target of ₹779.56 implies about 16% upside across 9 analysts. It clears 3 of 13 investability checks, with durability 14, valuation 17 and momentum 73 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹484.75. Low-confidence estimate — limited data.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-13.54% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Sell31Piotroski F-score 6/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 1.9%
- Fail: Low debt (D/E < 0.5): 1.23x
- Fail: Positive free cash flow
- Pass: Revenue growth > 10%: 12%
- Fail: Earnings growing: -71%
- Fail: Net margin ≥ 10%: 0.5%
- Fail: Current ratio > 1.5: 1.12
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Fail: Altman Z in safe zone: Z 2.73
- Fail: Piotroski ≥ 7: 6/9
Quarterly results
Annual financials
Shareholding
- Promoter70.6%
- Institutions16.5%
- Public & other12.9%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bear case
Weaknesses
- Low return on equity (1.9%).
- High debt relative to equity.
Threats
- Earnings contracting year on year.
- Rich valuation versus sector peers.
About HealthCare Global Enterprises Limited
HealthCare Global Enterprises Limited operates hospitals and diagnostic centers offering oncology services across India and internationally. Its offerings include cancer diagnostics through genomics, molecular diagnostics, digital PET, and digital pathology, along with treatment services spanning medical oncology, haemato-oncology, radiation oncology, surgical oncology, and molecular imaging. The company also provides laboratory tests, home health services, and preventive oncology programs.
HealthCare Global Enterprises Limited — frequently asked questions
Is HealthCare Global Enterprises Limited a buy, hold or sell?
StocksWizard currently rates HealthCare Global Enterprises Limited (HCG) a Sell, based on a blended score of 31/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is HealthCare Global Enterprises Limited's fair value?
Our blended DCF and relative-valuation model estimates HealthCare Global Enterprises Limited's fair value at about ₹605.94, versus a current price of ₹671.2 — roughly 10% downside. On that basis the stock looks fairly valued.
Is HealthCare Global Enterprises Limited financially healthy?
HealthCare Global Enterprises Limited scores 43/100 on our financial-health model, placing it in the grey band on the Altman Z-score, with a Piotroski F-score of 6/9.
How has HealthCare Global Enterprises Limited's share price performed?
HealthCare Global Enterprises Limited is up 9% over three months, and last traded at ₹671.2. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.